title: Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations.
abstract: BACKGROUND
  It has previously been shown that a combination of erythromycin and benzoyl peroxide is superior to either ingredient when used alone in the treatment of acne. A clindamycin/benzoyl peroxide combination gel might have an advantage over erythromycin/benzoyl peroxide gel because the former does not require refrigeration after it is dispensed.
  
  
  OBJECTIVE
  Our purpose was to determine the efficacy and safety of a combination clindamycin/benzoyl peroxide gel when compared with benzoyl peroxide, clindamycin, or vehicle gels.
  
  
  METHODS
  In two double-blind, randomized, parallel, vehicle-controlled trials, patients were treated for 11 weeks with once-nightly application of one of the above preparations. Evaluations were performed at 2, 5, 8, and 11 weeks and included lesion counts and assessment of global responses and irritant effects.
  
  
  RESULTS
  A total of 334 patients completed the study. All three active preparations were significantly superior to the vehicle in global improvement and in reducing inflammatory lesions and noninflammatory lesions. The combination gel was significantly superior to the two individual agents in global improvement and reduction of inflammatory lesions and also to the clindamycin gel in reducing noninflammatory lesions. There was no significant difference in tolerance to the active gels versus the vehicle gel.
  
  
  CONCLUSIONS
  In the treatment of acne, topical clindamycin/benzoyl peroxide combination gel is well tolerated and superior to either individual ingredient.
authors.affiliation: Department of Medicine, Pennsylvania State University College of Medicine, Hershey, USA.
authors.forename: D P
authors.initials: DP
authors.lastname: Lookingbill
authors.forename: D K
authors.initials: DK
authors.lastname: Chalker
authors.forename: J S
authors.initials: JS
authors.lastname: Lindholm
authors.forename: H I
authors.initials: HI
authors.lastname: Katz
authors.forename: S E
authors.initials: SE
authors.lastname: Kempers
authors.forename: C J
authors.initials: CJ
authors.lastname: Huerter
authors.forename: J M
authors.initials: JM
authors.lastname: Swinehart
authors.forename: D J
authors.initials: DJ
authors.lastname: Schelling
authors.forename: H C
authors.initials: HC
authors.lastname: Klauda
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001585:Benzoyl Peroxide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002981:Clindamycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D004917:Erythromycin / Q000008:administration & dosage / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D005782:Gels; D006801:Humans; D007509:Irritants / Q000009:adverse effects; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D014677:Pharmaceutical Vehicles; D010919:Placebos; D012074:Remission Induction; D012449:Safety
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005782:Gels; D007509:Irritants; D007641:Keratolytic Agents; D014677:Pharmaceutical Vehicles; D010919:Placebos; D002981:Clindamycin; D004917:Erythromycin; D001585:Benzoyl Peroxide